Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...

Blood Cancer United's new research funding supports foundational science, AI, big data and global collaborations to improve patient outcomes WASHINGTON, Dec. 2, 2025 /PRNewswire/ ...

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...

The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents ...

Progress in the treatment of T-cell blood cancers – which are rare – has also been modest. So, much remains to be done to ...

In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...

On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as 'Juventas') announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) ...

The treatment effects on PFS were consistent regardless of modeling approach and for both targeted and nontargeted therapies.

EMA committee recommends orphan drug designation to BioInvent’s BI-1808 to treat cutaneous T-cell lymphoma: Lund, Sweden Tuesday, November 18, 2025, 11:00 Hrs [IST] BioInvent In ...

And they received FDA support for Orphan Drug Designation and Fast Track Designation and they've got the opportunity to look at the IIb turning into a registration study, and that opens up the ...